(secondQuint)Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva.

 OBJECTIVES: - Determine the therapeutic activity of paclitaxel in patients with locally advanced, metastatic, or recurrent squamous cell carcinoma of the vulva.

 - Determine the objective response rate and duration of response in these patients treated with this drug.

 - Determine the acute side effects of this drug in these patients.

 OUTLINE: This is a multicenter study.

 Patients receive paclitaxel IV over 3 hours on day 1.

 Treatment repeats every 21 days for a maximum of 10 courses in the absence of disease progression or unacceptable toxicity.

 Patients are followed every 9 weeks.

 PROJECTED ACCRUAL: A total of 16-29 patients will be accrued for this study.

.

 Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva@highlight

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

 PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have locally advanced, metastatic, or recurrent cancer of the vulva.

